Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia
Andreas Burchert(Philipps University of Marburg), Andreas Neubauer(RWTH Aachen University), Larissa Odyvanova(Mologen (Germany)), Andreas Hochhaus(Jena University Hospital), Barbara Denecke(Mologen (Germany)), Cornelia Brendel(Philipps University of Marburg), Harald Gschaidmeier(Novartis (Germany)), Stefan Wölfl(Institute of Molecular Biotechnology), Thomas Berg(Leipzig University of Applied Sciences), Martin C. Müller(Universität Hamburg), Manuel Schmidt(Mologen (Germany)), Burghardt Wittig, Rüdiger Hehlmann(Heidelberg University), Dali Cai(First Hospital of China Medical University), Tanja Lahaye(Heidelberg University)
Cited by 136
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877